Tag: gene

Cheyenne, Wyoming, July 23, 2026 (GLOBE NEWSWIRE) -- Core Axis, a health brand founded by MC Bio-Logic LLC, announces the upcoming launch of its daily supplement protocol developed with Hashimoto's thyroiditis in mind. Hashimoto's thyroiditis is the autoimmune condition that affects an estimated five million Americans and remains the leading cause of hypothyroidism in the United States. Designed using evidence-based ingredient selection and clinically relevant dosages, the new protocol addresses nutritional factors relevant to individuals with autoimmune thyroid conditions rather than providing general thyroid support. The company is now inviting individuals to join its early access waitlist ahead of the official product launch.

NFM Lending and its Family of Lenders are proud to announce that CEO Bob Tyson is featured this month in The CEO Magazine, where he is recognized for his leadership, vision, and culture-first mindset

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4^th floor, 75013 Paris, France.

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
—Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—